Перекрестные исследования в медицине и здравоохранении

В данной статье описан дизайн перекрестного исследования, а также представлен его частный, гибридный вариант – «случай–перекрест». Изложены методологические особенности, описаны основные научные вопросы, на которые позволяют дать ответы данные исследования,. Описаны возможности интерпретации полученной информации. Обобщены достоинства и недостатки обоих дизайнов. Представлены и проанализированы примеры перекрестных исследований в медицинской литературе.

1. Холматова К. К., Харькова О. А., Горбатова М. А., Гржибовский А. М. Гибридные исследования в медицине и здравоохранении // Морская медицина. 2022. Т. 8, No. 3. С. 105–117 [Khomatova K. K., Kharkova O. A., Gorbatova M. A., Grjibovski A. M. Hybrid studies in medicine and public health. Marine Medicine, 2022, Vol. 8, No. 3, pp. 105–117 (In Russ.)]. doi: 10.22328/2413-5747-2022-8-3-105-117.

2. Piantadosi S. Crossover Designs. In: Piantadosi Steven. Clinical Trials: A Methodologic Perspective. 2nd ed. Hobaken N. J.: John Wiley and Sons Inc, 2005. ISBN: 978-0-471-74013-1.

3. Качественная клиническая практика с основами доказательной медицины. Учебное пособие для системы послевузовского и дополнительного профессионального образования врачей. Под ред. Р. Г. Оганова. М.: СилицеяПолиграф; 2011. 136 с. [Good clinical practice with basics of evidence-based medicine. Textbook for the postgraduate and additional professional education of physicians. Edited by R. G. Oganov. Moscow: SilitseaPoligraf; 2011, 136 p. (In Russ.)].

4. Sibbald B., Roberts C. Understanding controlled trials. Crossover trials. BMJ, 1998, Vol. 316, P. 1719. doi: 10.1136/bmj.316.7146.1719.

5. Wang T., Malone J., Fu H., Heilmann C., Qu Y., Huster W. J. Crossover design and its application in late-phase diabetes studies. J Diabetes, 2016, Vol. 8, No. 5, pp. 610–618. doi: 10.1111/1753-0407.12412.

6. Li B., Zhou Z., Zhang L., Yang Y. Testing treatment-by-period interaction in four-period crossover trials. Pharm Stat, 2020, Vol. 19, No. 2, pp. 145–163. doi: 10.1002/pst.1975.

7. Senn S. Cross-over trials in clinical research. 2nd ed. West Sussex, John Wiley & Sons. 2002, pp 35–88. ISBN: 978-0-471-49653-3.

8. Ratkowsky D., Evans M., Alldredge J. Cross-over experiments. Boca Raton, CRC Press. 2019, pp 77–120. eBook ISBN: 9780367813208.

9. Lim C.Y., In J. Considerations for crossover design in clinical study. Korean J Anesthesiol, 2021, Vol. 74, No. 4, pp. 293–299. doi: 10.4097/kja.21165.

10. Cleophas T. J. A simple method for the estimation of interaction bias in crossover studies. J Clin Pharmacol, 1990, Vol. 30, No. 11, pp. 1036–1040. doi: 10.1002/j.1552-4604.1990.tb03591.x.

11. Wellek S., Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int, 2012, Vol. 109, No. 15, pp. 276–281. doi: 10.3238/arztebl.2012.0276.

12. Zhang Z. Case-crossover design and its implementation in R. Ann Transl Med, 2016, Vol. 4, No. 18, pp. 341. doi: 10.21037/atm.2016.05.42.

13. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol, 1991, Vol. 133, No. 2, pp. 144–153. doi: 10.1093/oxfordjournals.aje.a115853.

14. Consiglio G. P., Burden A. M., Maclure M., McCarthy L., Cadarette S. M. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiol Drug Saf, 2013, Vol. 22, No. 11, pp. 1146–1153. doi: 10.1002/pds.3508.

15. Dharmarajan S., Lee J.Y., Izem R. Sample size estimation for case-crossover studies. Stat Med, 2019, Vol. 38, No. 6, pp. 956–968. doi: 10.1002/sim.8030.

16. Szyszkowicz M. Case-Crossover Method with a Short Time-Window. Int J Environ Res Public Health, 2019, Vol. 17, No. 1, P. 202. doi: 10.3390/ijerph17010202.

17. Wang X., Wang S., Kindzierski W. Eliminating systematic bias from case-crossover designs. Stat Methods Med Res, 2019, Vol. 28, No. 10–11, pp. 3100–3111. doi: 10.1177/0962280218797145.

18. Hu C., Gao D., Li D., Zhou D., Zhang L. Chinese- and French-Manufactured Immediate-Release Glucophage® Bioequivalence: A Randomized, Open-Label, Crossover Study. Drugs R D., 2022, Vol. 22, No. 4, pp. 301–309. doi: 10.1007/s40268-022-00405-3.

19. Ishak K. J., Proskorovsky I., Korytowsky B., Sandin R., Faivre S., Valle J. Methods for Adjusting for Bias Due to Crossover in Oncology Trials. Pharmaco Economics, 2004, Vol. 32, pp. 533–546. doi: 10.1007/s40273-014-0145-y.

20. Prasad V., Grady C. The misguided ethics of crossover trials. Contemp Clin Trials, 2014, Vol. 37, No. 2, pp. 167–169. doi: 10.1016/j.cct.2013.12.003.

21. Latimer N. R., Abrams K. R., Lambert P. C. Crowther M. J., Wailoo A. J., Morden J. P., Akehurst R. L., Campbell M. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations. Med Decis Making, 2014, Vol. 34, No. 3, pp. 387–402. doi: 10.1177/0272989X13520192.

22. Jönsson L., Sandin R., Ekman M., Ramsberg J., Charbonneau C., Huang X., Jönsson B., Weinstein M.C., Drummond M. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health, 2014, Vol. 17, No. 6, pp. 707–713. doi: 10.1016/j.jval.2014.06.006.

23. Isbary G., Staab T. R., Amelung V. E., Dintsios C. M., Iking-Konert C., Nesurini S. M., Walter M., Ruof J. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany. Value Health, 2018, Vol. 21, No. 6, pp. 698–706. doi: 10.1016/j.jval.2017.09.010.

24. Swain S. M., Baselga J., Kim S. B., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J. M., Schneeweiss A., Heeson S., Clark E., Ross G., Benyunes M. C., Cortés J. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med, 2015, Vol. 372, No. 8, pp. 724–734. doi: 10.1056/NEJMoa1413513.

25. Auger N., Bilodeau-Bertrand M., Ayoub A., Potter B.J. Matters of the Heart: Case-Crossover Analysis of Myocardial Infarction on Valentine’s Day. CJC Open, 2021, Vol. 3, No. 8, pp. 1075–1078. doi: 10.1016/j.cjco.2021.03.013.

26. Mohammad M. A., Karlsson S., Haddad J., Cederberg B., Jernberg T., Lindahl B., Fröbert O., Koul S., Erlinge D. Christmas, national holidays, sport events, and time factors as triggers of acute myocardial infarction: SWEDEHEART observational study 1998–2013. BMJ, 2018, Vol. 363, k4811. doi: 10.1136/bmj.k4811.

27. Redelmeier D. A., Tibshirani R. J. Association between cellular-telephone calls and motor vehicle collisions. N Engl J Med, 1997, Vol. 336, No. 7, pp. 453–458. doi: 10.1056/NEJM199702133360701.